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NUTRACEUTICAL POTENTIAL FOR ALZHEIMER’S DISEASE 
TREATMENT  
Alex Gewecke  
Mentor: Dr. Surabhi Chandra, Department of Biology  
                                                         ABSTRACT           
            Alzheimer’s disease (AD) is a progressive disorder involving buildup of excessive amounts 
of proteins such as beta amyloid in the brain that leads to memory loss, inability to perform daily 
functions, and an early death. By 2060, the number of cases is forecast to nearly triple current 
numbers. Age is the primary risk factor for AD and no new drugs have been approved since 2003. 
Nutraceuticals, a broad category of substances that can be utilized for both medicinal and 
nutritional purposes may be able to help, which is why they are being more widely researched. 
Overall, a number of attempts to use isolated nutrients such as vitamins have failed to display in 
showing any improvement in AD. In fact, some of them have even worsened the disease, and the 
ones showing major improvements had some methodological flaws. However, isolated non-
nutritive antioxidants and peptides exert some beneficial effects in vitro, in vivo, and in clinical 
trials, while non-isolated whole food extracts and melatonin show potential in clinical trials. 
Unfortunately, no known treatment can reverse disease progression, though some can slow it. Most 
of the treatments covered in this article had few side effects. Future research could combine some 
of these treatments and provide a possible natural prevention/treatment option for AD. 
INTRODUCTION 
          Alzheimer’s disease (AD) is a progressive disorder characterized by the buildup of excessive 
amounts of certain proteins in the brain that lead to memory loss, inability to perform daily 
functions, and eventual death. It is believed to affect approximately 5.5 million Americans, and 
usually becomes noticeable in the seventh decade of life. (1). For those at risk, age is the primary 
risk factor, with an exponential increase in incidence after 65. Certain genes, diet, and high blood 
pressure and cholesterol may also augment disease risk. (2). Recent advances in medical 
technology have enabled detection of the disease before serious symptoms arise, defined as 
preclinical AD. This is important because earlier treatment is likely to be more effective at stalling 
AD symptoms. However, it is difficult to define the beginnings of preclinical AD, since there is 
contention as to whether it should be diagnosed at the first signs of cognitive decline or biomarkers 
from lab results (3). A definitive AD diagnosis requires postmortem autopsy (4). Attempts to 
develop drugs to delay or treat AD have been mostly unsuccessful, with no new drugs having been 
approved since 2003. A number of them tried to target the beta-amyloid plaques that form in the 
brain, which is the hallmark symptom of the disease. As of early 2019, 132 agents were in clinical 
trials for AD (5). Since most of the synthetic chemotherapeutics have side effects, focus has been 
directed towards use of nutraceuticals, including curcumin, ginger, garlic, and essential oils, which 
have been used as traditional medicines in certain cultures.  
Nutraceuticals are a broad category of substances that can be utilized for both medicinal 
and nutritional purposes. Lately, they have been more widely explored for medical research due 
to the belief that they may harbor potential to treat a wide array of chronic diseases. For example, 
an antioxidant found in certain foods called quercetin can prevent LDL-C cholesterol oxidation in 
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blood vessel endothelia, acting like a sponge soaking up free radicals (6). Genetics can also play a 
role in developing AD. It is surmised that certain dietary components can impact how genes 
associated with AD and other diseases are expressed, though few papers have examined this. Most 
of the nutraceuticals that have been examined are compounds derived from edible plants, such as 
catechins, resveratrol, and flavanols (7). Therefore, it may be worthwhile to search for a specific 
food, compounds isolated from food, or a combination of natural and/or synthetic drugs that can 
treat or reverse AD. Most research is currently done using isolated compounds. (Figure 1).  
 
 
          AD cases are expected to increase from approximately 5 million to 13.9 million in 2060 (8). 
Some potential epigenetic targets are DNA and histone methylation, acetylation, and 
phosphorylation, since memory formation at least partially depends on these chemical reactions. 
This is supported by the observation that most cases of AD are not associated with known genetic 
mutations and present late in life. If familial genetic mutations were the sole cause, it would be 
possible to identify future AD patients from birth (9).  
Quercetin, found in apples and onions, among other foods, can prevent the death of 
endothelial cells by protecting them from oxidative stress (6). Crocin, a compound found in 
Saffron, was found to minimize the deleterious effects of long-term stress on memory and learning 
(10). Multiple other compounds described in this review had positive effects in rodents but had 
failed to demonstrate those same effects in human randomized clinical trials. Quercetin and saffron 
are explored later. Figure 2 shows the study design of trials reviewed in this article.  
  
Figure 1:Research articles on different food items used to treat AD  
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ISOLATED NUTRIENTS AND SUPPLEMENTS TO TREAT AD 
Nutraceuticals can fall into several distinct categories. This can include food, food 
components, and vitamins (11). Limited research suggests sleep deprivation and AD exacerbate 
one another (12). Melatonin is a hormone that is chiefly released to induce the body to fall asleep. 
To explore whether melatonin supplementation improved symptoms, a formula that releases 
melatonin slowly was developed because the body normally metabolizes excess melatonin 
quickly. This double-blind placebo-controlled trial found that treatment resulted in an 
improvement in the ability for patients to carry out daily activities as well as sleep quality, though 
other aspects of AD were mostly unchanged (13). Thus, adding slow-releasing melatonin to other 
treatments may help patients with mild to moderate disease progression.  
Docosahexaenoic acid (DHA) is an integral lipid in the brain. Preformed DHA can be 
found in fish and supplements, but humans can also synthesize it from Alpha-linolenic acid (ALA), 
found in vegetable oils, and fortified foods are available. Variations in blood levels partially 
depend on differential consumption of these sources (14). Unsurprisingly, increased intake is 
associated with a reduced risk of AD. In this double-blind trial, 402 patients without severe disease 
progression were randomized to either 2 grams of DHA daily or placebo. In animal studies, DHA 
had shown potential to treat some symptoms, but this trial found no beneficial effects. The 
researchers did suspect that DHA might still be beneficial if taken before clinical symptoms, that 
oxidation of DHA after consumption might limit its ability to benefit patients, and that certain 
genes may influence its effectiveness. (15). Unfortunately, in 2014, when 47 different omega 3 
supplement brands were sampled to determine the actual quantities of the stated active ingredients, 
there was extensive variation in the levels of DHA and other lipids, with most containing less than 
stated on the labels (16). Accordingly, concerns over whether some DHA supplements contain the 
levels described on the labels are valid. 
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Figure 2: Biological models used with nutraceuticals in AD. Randomized 
double-blind placebo-controlled study design is the most conclusive. 
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N-Palmitoylethanolamide (PEA) is a lipid commonly found in soy lecithin, egg yolks, and 
peanuts that controls other processes. Preclinical evidence suggests that it is very safe and can be 
used to treat atherosclerosis, inflammation, and pain, and some in vitro evidence suggests that PEA 
has the ability to attenuate some of the harmful effects of beta amyloid, including astrogliosis and 
neuroinflammation. In certain strains of live mice, PEA inhibited reactive gliosis and nutritionally 
supported neurons (17). Unfortunately, there is no human clinical evidence for the efficacy of PEA 
in the treatment of individuals with AD because not much is known about its pharmacokinetics, 
though one study found that ultra-micronized PEA could slow the progression of Parkinson’s 
disease (18). Accordingly, more research on this compound’s metabolism and subsequent clinical 
trials are needed to determine if it has potential for treatment of AD. 
Previously, a phase I clinical trial had been done on supplementation of a combination of 
folate, alpha tocopherol, vitamin B12, two modified amino acids and acetyl-L-carnitine, which 
safely ameliorated some symptoms of dementia. This phase II double-blind placebo-controlled 
clinical trial with the same ingredients found that after 3 and 6 months, respectively, there were 
marked improvements in multiple measures of cognitive function, but these were accompanied 
with large standard errors, and these effects were limited to patients with mild to moderate 
dementia. Following this was an open-label extension, and those who had received placebo 
previously had cognitive improvement approaching levels comparable to the treated group in the 
blinded portion of the trial. Nutritional status was not measured, and patients were not separated 
into categories reflecting this, though it is mentioned that if this had been done, the beneficial 
effects of the treatment may have been cancelled out by any remaining damage from malnutrition 
in those with poor nutritional status (19). 
In a double-blind placebo-controlled trial examining effects on AD markers, 78 
participants were given either Vitamin E, C, and ALA, only Coenzyme Q, or a placebo. In the 
group taking all three supplements, there was a decrease in cognitive function despite a coinciding 
decrease in oxidative stress markers, and no effect on markers of tau proteins. This raises concerns 
for future trials involving isolated nutrients and antioxidants for AD treatment, particularly since 
treatment will need to be administered long-term to see regression of the disease (11). It is also 
possible that drugs in isolation simply are incapable of having a dramatic effect on AD beyond 
correcting deficiencies.     
ISOLATED POLYPHENOLS AND EXTRACTS FOR AD TREATMENT 
Curcumin, the yellow pigment of the spice turmeric has traditionally been used to treat a 
wide variety of disorders, has a multitude of medicinal properties, and is extremely cheap and safe, 
resulting in its status as the most studied compound as of 2015 (20). Curcumin is poorly absorbed, 
so it has been difficult to conduct clinical trials with it. However, it has some naturally occurring 
variants or analogues including bisdemethoxycurcumin, which has been demonstrated to exert 
stronger anti-inflammatory effects in rats. In blood cells of AD patients, curcumin dissolves some 
beta amyloid plaque (21). Future research could be done on curcumin, bisdemethoxycurcumin, 
and other analogues in humans. 
Quercetin has been proposed to cross the blood brain barrier, allowing it to target the 
pathologies of AD (22). A strain of aged mice that had accumulated a buildup of tau proteins were 
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treated with quercetin, and no deleterious side-effects were observed. Additionally, it protected 
neurons in the inferior portion of the hippocampus, and reversed buildup of beta amyloid and tau 
proteins. It also showed a tangible improvement in memory and spatial learning and an apparent 
reduction in anxiety (23). 
Colostrinin is a patented polypeptide rich in proline isolated from colostrum. It has been 
demonstrated in a small-scale trial to help treat AD patients by improving their social capabilities, 
mood, and motivation at 100 micrograms every other day. Neuroprotection was also conferred for 
human neuroblastoma cells mixed with the amyloid. A possible mechanism is through reduction 
of stickiness of beta amyloids 1-40, but it might also lower the toxicity of beta amyloid itself by 
preventing beta-amyloid induced neural apoptosis. (24).  
WHOLE FOODS AND FOOD EXTRACTS 
Rice bran is traditionally used as a cheap byproduct to feed livestock and was broken down 
into small peptides to be investigated in a human neural cancer cell culture for activity against AD. 
Previous research on extracts from the bran reported a noticeable effect on cancer. The cells were 
first treated with amyloid to simulate AD then treated with the fractionated rice bran peptides. 
Toxicity from the beta amyloid was inhibited by up to 45% in the cells treated with both amyloid 
and peptides compared to those that were treated with amyloid alone, but complex molecular 
interactions make it difficult to establish a mechanism of action (25). 
Saffron has the ability to combat cancer, inflammation, pain, atherosclerosis, hepatic 
damage, hyperlipidemia, and hypertension. Some clinical trials have shown that saffron possesses 
similar anti-AD properties as the conventional approved therapeutics such as Donepezil and 
Memantine, but with fewer and lesser side effects. Saffron has not been tried in combination 
therapies yet (26). 
Green tea extract was used in a clinical trial conducted at Daejeon University Oriental 
Hospital in Korea. Amongst the study participants, 91 otherwise healthy people aged 40-75 years 
with memory complaints were randomized to either capsules with green tea extract and L-theanine 
or placebo capsules twice daily 30 minutes after meals. The green tea extract improved some 
measures of cognitive function, including color reading and an increase in theta brain waves, 
suggesting augmented mental performance, but only marginally. There were markedly more 
female participants than males, but it is unknown whether this affected the results. Additionally, 
as with the phase II clinical trial evaluating six isolated nutrients, the data could be put into a more 
useful context if nutritional status were established for each participant prior to the study (27).  
CONCLUSION  
          Currently approved therapeutics for chronic conditions such as hypertension, pain, diabetes, 
etc. are associated with moderate to severe side effects.  For example, statins, which are the 
standard hypercholesterolemia treatment can occasionally cause cause muscle pain and 
rhabdomyolysis (28). Compounds found in plant foods, such as curcuminoids and sterols, can 
lower cholesterol but have an impressive safety profile (29). They also have other beneficial effects 
(20). This has prompted further investigation into the use of nutraceuticals for the treatment of 
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AD. Overall, numerous attempts to use isolated nutrients such as vitamins have failed to show 
improvement. One trial using multiple supplements accelerated disease progression (11), and the 
ones showing major improvements had the limitation that nutritional status prior to the study was 
not evaluated (19, 25). Further research is necessary to investigate the extent of benefits provided 
by PEA and the beneficial combination of supplements found in one trial. Isolated non-nutritive 
antioxidants including curcumin and fractionated rice bran peptides exert some beneficial effects 
on disease progression in vitro, in vivo, and in clinical trials. Similarly, non-isolated whole food 
extracts and melatonin also show effectiveness in clinical trials. It is important to recognize that 
there is no known treatment that can reverse disease progression. Figure 3 provides a graphical 
representation of how the treatments affected disease progression. In addition, most of these 
treatments showed low toxicity and had few side effects. Research into nutraceutical use in the 
treatment of AD is still in its infancy, but the results from some of these trials are promising and 
warrant further investigation. Future research might be done on combinations of the most effective 
treatments today and replication of previous trials. 
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Figure 4: Summary of figures 1-3. Detailed table below figure. 
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Table 1: Detailed summary of all the treatments categories, compounds, study designs, and published 
results. DBPCCT=double-blind placebo-controlled clinical trial, INS=isolated nutrients and 
supplements, IPE=isolated polyphenols and extracts, WF=whole foods and whole food extracts, 
MAA= modified amino acid, vit=vitamin, G=group                     
 Names Design Result 
INS Slow-release melatonin DBPCCT Some benefits 
 Docosahexaenoic acid (DHA) DBPCCT No definite benefits 
 N-Palmitoylethanolamide (PEA) 
Live Mouse 
Model Some benefits 
 
Combined: folate, vit E, vit B12, two 
MAAs and acetyl-L-carnitine DBPCCT Some benefits 
 
Combined: G1: Vitamin E, C, ALA G2: 
Coenzyme Q, G3: Placebo DBPCCT Some harmful effects 
IPE Curcumin 
Human Cell 
Culture Some benefits 
 Quercetin 
Live Mouse 
Model Some benefits 
 Colostrinin DBPCCT Some benefits 
WF Saffron DBPCCT 
Disease delay with fewer side 
effects than conventional treatments  
Green Tea Extract DBPCCT Some benefits 
 Fractionated Rice Bran Peptides 
Human Cell 
Culture Some benefits 
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